Campaign: Diabetic Neuropathy

Demyelination

Demyelination is a prominent feature of clinical neuropathy, but absent from rodent models of diabetes (barring occasional reports of fixation artifact). Some markers of Schwann cell fidelity are disrupted, but myelin remains resplendently unchanged in the face of long periods of excess glucose exposure. Do we have to resort to the usual handwaving of "absoute duration of diabetes" being an explanatory factor when the ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Neuropathy

Pipeline fracture

1001 drugs fix NCV slowing in diabetic rodents but none have translated to clinical use. Does NCV slowing in short term rodents have a different pathogenesis to that in humans?

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Uropathy

Follow up from Urologic Complications of Diabetes Meeting

Rough drafts of Breakout Group Reports

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Complications (General)

How does diabetes affect regeneration and repair?

Tissue injury in diabetes results from cell damage and death, impaired communication among cells, dysfunction of nerves and blood vessels, and detrimental responses to systemic signals, such as inflammation. The development of the clinical manifestations depends on tissue-specific responses to injury and impairments in repair and regenerative processes. The knowledge base of the pathologic process in different tissues ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Nephropathy

How do we promote translation in DN?

Mechanisms should be established to support research on drug and biologic development that will not be supported by industry. For example, expansion of programs such as the NIH-supported Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) program, and establishment of clinical trial networks, would allow potential therapies to be developed and tested in early Phase I and II trials that could lead to NIH ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Nephropathy

Can miRNA signatures be exploited to diagnose and treat DN?

MicroRNAs are short ribonucleotides that bind to messenger RNA to modify protein translation or promote RNA degradation. Knowledge of the function and regulation of miRNA is rapidly expanding. They appear to be sensitive to the extracellular environment and could be important regulators of a cell’s response to diabetes. Can miRNA signatures detect early signs of DN? Can knowledge of miRNA signatures be translated ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Nephropathy

Can stem cells repair and reverse DN?

Normally, metabolic and ischemic insults stimulate repair and regeneration. In diabetes, however, these processes are impaired. Recent advances in cell reprogramming hold great promise for future cell replacement therapies. How are specific populations of stem/progenitor cells affected by diabetes? Are these abnormalities reversible through optimal diabetes treatment or therapies targeted to stem/progenitor cells? ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Nephropathy

What new technologies will lead the field of DN forward?

Translation of the knowledge of the molecular consequences of diabetes to effective therapies requires better measures of disease progression, faithful models of the molecular and cellular pathology, and application of cutting-edge technologies. Validated biomarkers and surrogate end points will allow rapid screening of clinical interventions prior to larger clinical trials, and can assess risk factors and treatment adequacy ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Nephropathy

How will personalized medicine alter patient care in DN?

One explanation for the discordant response of agents that treat complications in rodents versus humans is that deleterious pathways that are responsive to a certain drug may be widely expressed in inbred animal models, but expressed in only a small number of individuals. Should some agents be tested in primates or some other larger mammal? Pharmacogenomic, pharmacometabolomic, and pharmacoproteomic approaches could ...more »

Submitted by

Voting

0 votes
Active

Campaign: Diabetic Nephropathy

Will systems biology discover new pathways and targets for DN?

There has been an explosion of new genetic, biochemical, and cell biologic techniques. Appropriate systems biology tools are needed to facilitate integration of genotyping information, mRNA expression, microRNA expression, promoter analysis, proteome expression, and metabolome profiles in order to identify key biological processes and their interactions. In addition to better computational tools, a deeper understanding ...more »

Submitted by

Voting

1 vote
Active

Campaign: Diabetic Nephropathy

What are the key genetic and epigenetic determinants of DN?

Metabolic control alone does not predict an individual’s risk for diabetic complications. Family studies suggest that genetic factors play an important role in the predisposition for a specific type of complication and its progression. In addition to more classic genetics, research in this area has expanded to epigenetics and non-coding RNA. Epigenetic marks include modifications to the DNA or chromatin that do not ...more »

Submitted by

Voting

1 vote
Active

Campaign: Diabetic Nephropathy

Is mitochondrial (dys)function a major component of DN

Genetic mutations in mitochondrial fission/fusion proteins and changes in ROS production have been linked to diabetic complications. Why does the apparently global pathogenic mechanism of increased mitochondrial activity have variable consequences in different cell types? Can we develop better tools to assess mitochondrial function, transport, number, and fission/fusion states? Can we improve mitochondrial function ...more »

Submitted by

Voting

0 votes
Active